Compounding formularies change quarterly
These studies show us that for people with diabetes, there is significant risk reduction of heart attack and kidney disease with semaglutide, says Dr Winnett
To stay updated on science and science-related tools, people can follow Huberman Lab on social media platforms such as Instagram, X, Threads, Facebook, and LinkedIn, where distinct content is shared, some of which overlaps with the Huberman Lab podcast 1m30s
Disclosures Sanjay Kalra has received speaker fees from Eli Lilly, Novo Nordisk and Sanofi and is a member of the journals Editorial Board
Decotiis, noting that "women do very, very well on this medication" due to this hormonal interaction